Company Registration No. 14210304 (England and Wales)
S.RAGNO PHARMA CONSULTING LTD
Unaudited accounts
for the period from 1 November 2023 to 31 July 2024
S.RAGNO PHARMA CONSULTING LTD
Unaudited accounts
Contents
S.RAGNO PHARMA CONSULTING LTD
Company Information
for the period from 1 November 2023 to 31 July 2024
Company Number
14210304 (England and Wales)
Registered Office
FLAT 502 10 CUTTER LANE
LONDON
SE10 0XX
ENGLAND
Accountants
Richard Matthew Accountancy Ltd
Milner
Cowfold Road
Coolham
West Sussex
RH13 8QJ
S.RAGNO PHARMA CONSULTING LTD
Statement of financial position
as at 31 July 2024
Cash at bank and in hand
-
312,796
Creditors: amounts falling due within one year
-
(73,014)
Net current assets
239,449
239,782
Net assets
239,449
242,365
Called up share capital
1
1
Profit and loss account
239,448
242,364
Shareholders' funds
239,449
242,365
For the period ending 31 July 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 31 July 2024 and were signed on its behalf by
S Ragno
Director
Company Registration No. 14210304
S.RAGNO PHARMA CONSULTING LTD
Notes to the Accounts
for the period from 1 November 2023 to 31 July 2024
S.RAGNO PHARMA CONSULTING LTD is a private company, limited by shares, registered in England and Wales, registration number 14210304. The registered office is FLAT 502 10 CUTTER LANE, LONDON, SE10 0XX, ENGLAND.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous period, and also have been consistently applied within the same accounts.
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Fixtures & fittings
20% straight line
Computer equipment
1/3rd straight line
The company has ceased trading and the director's intention is to liquidate the company.
4
Tangible fixed assets
Fixtures & fittings
Computer equipment
Total
Cost or valuation
At cost
At cost
At 1 November 2023
1,353
2,251
3,604
Disposals
(1,353)
(2,251)
(3,604)
At 1 November 2023
271
750
1,021
On disposals
(271)
(750)
(1,021)
At 31 October 2023
1,082
1,501
2,583
S.RAGNO PHARMA CONSULTING LTD
Notes to the Accounts
for the period from 1 November 2023 to 31 July 2024
Amounts falling due within one year
6
Creditors: amounts falling due within one year
2024
2023
Taxes and social security
-
66,339
Loans from directors
-
4,988
7
Average number of employees
During the period the average number of employees was 0 (2023: 0).